It was a busy week for Australia’s top brokers. This has led to a number of broker notes being released.
Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
Hub24 Ltd (ASX: HUB)
According to a note out of Bell Potter, its analysts have retained their buy rating and $110.00 price target on this investment platform provider’s shares. The broker highlights that despite early weakness, global equity markets recovered and posted outsized returns for the June quarter. In light of this, Bell Potter has upgraded its model to reflect strong positive mark-to-markets. Outside this, the broker believes that a heavy decline since its November peak, despite earnings upgrades and further positive adjustments yet to flow through, has created a buying opportunity for investors. The Hub24 share price ended the week at $81.04.
Northern Star Resources Ltd (ASX: NST)
A note out of Citi reveals that its analysts have retained their buy rating and $29.70 price target on this gold miner’s shares. The broker was pleased with Northern Star’s quarterly update, which revealed gold sales comfortably ahead of expectations during the fourth quarter. It notes that this helped take Northern Star’s gold sales beyond its revised guidance for FY 2026. As a result of this strong performance, Citi continues to see plenty of value in the company’s shares at current levels. The Northern Star share price was fetching $22.16 at Friday’s close.
ResMed Inc. (ASX: RMD)
Analysts at Morgans have retained their buy rating and $41.72 price target on this sleep disorder treatment company’s shares. According to the note, the broker highlights that ResMed’s shares have de-rated to just 16 times forward earnings. This is its lowest valuation in over a decade and comes despite the market continuing to forecast double-digit earnings per share growth. And while there are risks from GLP-1 therapies, an oral OSA therapy, and the potential re-entry of a key competitor next year, Morgans points out that current industry data and its operating performance provide limited evidence of a material deterioration in underlying demand. The ResMed share price ended the week at $30.50.
The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.
Should you invest $1,000 in Hub24 right now?
Before you buy Hub24 shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Hub24 wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Healthcare shares lead the ASX 200 again as sector rotation gathers pace
- Buy, hold, sell: Objective Corp, ResMed, and South32 shares
- 9 ASX 200 shares with renewed buy ratings for FY27
- 10 of the best ASX shares to buy in FY 2027
- Here are the top 10 ASX 200 shares today
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.